Mr. Peetz joined Tobira as chief financial officer and head of corporate development in 2014. At Tobira, Mr. Peetz led the financing and strategic efforts to take the company public via a reverse merger, fund the Phase 2b program of CVC for NASH, expand companyís pipeline and strategic process leading to a sale of Tobira to Allergan for up to $1.7 billion. Prior to joining Tobira, Mr. Peetz was vice president, finance & corporate development at Jennerex, Inc. While at Jennerex, Mr. Peetz led a $21 million private financing and the sale of the company to SillaJen for $150 million including milestones. Prior to Jennerex, Mr. Peetz was at Onyx Pharmaceuticals, Inc. (now Amgen), and had oversight of financial planning and analysis, corporate strategy, product lifecycle management and commercial roles on Nexavar®, Stivarga® and Kyprolis®. While at Onyx, Mr. Peetz supported public financings totaling nearly $300 million. Prior to Onyx, Mr. Peetz provided merger and acquisition advisory services at LaSalle Corporate Finance, a part of ABN AMRO, and held positions at Abgenix, Inc. and Solazyme, Inc.